title: Evolving therapies for hepatitis C virus in chronic kidney disease: the beginning of a new era.
abstract: The current review highlights recent advances in treatment of chronic hepatitis C virus infection using new classes of agents, direct-acting antivirals (DAAs), with a focus on the evidence for their use in the setting of chronic kidney disease (CKD) stages 4-5, hemodialysis, and kidney transplantation.
  
  
  
  DAA agents target-specific proteins involved in the hepatitis C virus life cycle and interrupt viral replication. Sustained virologic response, a marker of viral eradication, occurs in more than 90% of patients treated with DAA agents in the general population. Emerging data demonstrate similar sustained virologic response rates for specific DAA-based regimens in patients with CKD stages 4-5, hemodialysis patients, and kidney-transplant recipients.
  
  
  
  High sustained virologic response rates are seen with DAA agents in CKD populations. A thoughtful approach to the timing of treatment is required to facilitate timely access to kidney transplantation.
authors.affiliation: aRenal Section, Department of Medicine, Boston University School of Medicine bDivision of Infectious Diseases, Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
authors.forename: Craig E
authors.initials: CE
authors.lastname: Gordon
authors.forename: Claudia
authors.initials: C
authors.lastname: Nader
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016030:Kidney Transplantation; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000628:therapy
chemical_list: D000998:Antiviral Agents